Literature DB >> 30689030

[Reduced radiation-induced brain necrosis in nasopharyngeal cancer patients with bevacizumab monotherapy].

Cedric Oliver Carl1, Marvin Henze2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30689030     DOI： 10.1007/s00066-019-01425-w

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  13 in total

1.  Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis.

Authors:  Agnes S Chan; Mei-Chun Cheung; Stephen C Law; John H Chan
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

2.  [Brain metastasis versus radiation necrosis after head and neck cancer : Brain lesion after head and neck cancer].

Authors:  B Kofler; J Kerschbaumer; V H Schartinger; A Posch; E R Gizewski; G Widmann
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

3.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

4.  Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: report of 14 cases.

Authors:  Yong-gao Mou; Ke Sai; Zhen-ning Wang; Xiang-heng Zhang; Yan-chun Lu; Da-nian Wei; Qun-ying Yang; Zhong-ping Chen
Journal:  Head Neck       Date:  2010-12-06       Impact factor: 3.147

5.  Surgical techniques in radiation induced temporal lobe necrosis in nasopharyngeal carcinoma patients.

Authors:  Gobran Taha Ahmed Alfotih; Mei Guang Zheng; Wang Qing Cai; Xin Ke Xu; Zhen Hu; Fang Cheng Li
Journal:  Neurol Neurochir Pol       Date:  2016-03-07       Impact factor: 1.621

6.  Results of excision of cerebral radionecrosis: experience in patients treated with radiation therapy for nasopharyngeal carcinoma.

Authors:  Sui-To Wong; Ka-Tai Loo; Kwong-Yui Yam; Wai-Man Hung; Kam-Fuk Fok; Shing-Chau Yuen; Dawson Fong
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

7.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Authors:  Riccardo Soffietti; Ufuk Abacioglu; Brigitta Baumert; Stephanie E Combs; Sara Kinhult; Johan M Kros; Christine Marosi; Philippe Metellus; Alexander Radbruch; Salvador S Villa Freixa; Michael Brada; Carmine M Carapella; Matthias Preusser; Emilie Le Rhun; Roberta Rudà; Joerg C Tonn; Damien C Weber; Michael Weller
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

8.  Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging.

Authors:  Christopher M McPherson; Ronald E Warnick
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

9.  Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery.

Authors:  Dustin Boothe; Robert Young; Yoshiya Yamada; Alisa Prager; Timothy Chan; Kathryn Beal
Journal:  Neuro Oncol       Date:  2013-06-27       Impact factor: 12.300

Review 10.  Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its management.

Authors:  Jing Chen; Meera Dassarath; Zhongyuan Yin; Hongli Liu; Kunyu Yang; Gang Wu
Journal:  Radiat Oncol       Date:  2011-09-30       Impact factor: 3.481
View more
  2 in total

1.  [Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].

Authors:  Yi Chen; Xin Wang; Bing Sun; Maobin Meng; Enmin Wang; Zhiyong Yuan; Hongqing Zhuang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-05-16

Review 2.  Treatment of Radiation-Induced Brain Necrosis.

Authors:  Xiaojing Yang; Hanru Ren; Jie Fu
Journal:  Oxid Med Cell Longev       Date:  2021-12-24       Impact factor: 6.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.